优化流感中和抗体应答的佐剂比较研究
本研究系统比较了多种佐剂增强流感血凝素-铁蛋白纳米颗粒疫苗免疫应答的能力。TLR2、TLR4、TLR7/8、TLR9激动剂、角鲨烯水包油乳剂及STING激动剂均与HA-NPs兼容;将TLR7/8和TLR9配体直接偶联至纳米颗粒可诱导更强抗体应答,并使佐剂剂量较传统混合方式降低5000倍。水包油佐剂AF03在非人灵长类中诱导了对同源和异源H1N1病毒的中和应答。
要点
- HA-铁蛋白纳米颗粒与多种TLR激动剂、角鲨烯乳剂及STING激动剂兼容。
- TLR7/8和TLR9配体偶联纳米颗粒可增强抗体应答,佐剂剂量降低5000倍。
- AF03在非人灵长类中诱导对同源和异源H1N1病毒的中和应答。
核心结论
- AF03及某些TLR激动剂可增强流感疫苗接种后的强中和抗体应答,并可能改善抗体广度、效力及最终疫苗保护。
研究设计与样本
- 临床前研究:系统分析TLR激动剂等佐剂对HA-铁蛋白纳米颗粒疫苗免疫应答的影响,并在非人灵长类中测试AF03。
主要发现
- HA-NPs与TLR2、TLR4、TLR7/8、TLR9激动剂、角鲨烯水包油混合物及STING激动剂几乎均兼容。
- TLR7/8和TLR9配体化学偶联至HA-铁蛋白纳米颗粒后,诱导的抗体应答强于单独纳米颗粒。
- 偶联佐剂的纳米颗粒允许使用比传统混合方式低5000倍的佐剂剂量。
- AF03在非人灵长类中强烈诱导针对匹配和异源H1N1病毒的中和应答。
临床怎么用
- 提示AF03和特定TLR激动剂可作为流感疫苗佐剂候选,用于增强中和抗体应答及广度。
局限性
- 研究为临床前阶段,人体中的有效性及安全性尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Seasonal influenza vaccines represent a positive intervention to limit the spread of the virus and protect public health. Yet continual influenza evolution and its ability to evade immunity pose a constant threat. For these reasons, vaccines with improved potency and breadth of protection remain an important need. We previously developed a next-generation influenza vaccine that displays the trimeric influenza hemagglutinin (HA) on a ferritin nanoparticle (NP) to optimize its presentation. Similar to other vaccines, HA-nanoparticle vaccine efficacy is increased by the inclusion of adjuvants during immunization. To identify the optimal adjuvants to enhance influenza immunity, we systematically analyzed TLR agonists for their ability to elicit immune responses. HA-NPs were compatible with nearly all adjuvants tested, including TLR2, TLR4, TLR7/8, and TLR9 agonists, squalene oil-in-water mixtures, and STING agonists. In addition, we chemically conjugated TLR7/8 and TLR9 ligands directly to the HA-ferritin nanoparticle. These TLR agonist-conjugated nanoparticles induced stronger antibody responses than nanoparticles alone, which allowed the use of a 5000-fold-lower dose of adjuvant than traditional admixtures. One candidate, the oil-in-water adjuvant AF03, was also tested in non-human primates and showed strong induction of neutralizing responses against both matched and heterologous H1N1 viruses. These data suggest that AF03, along with certain TLR agonists, enhance strong neutralizing antibody responses following influenza vaccination and may improve the breadth, potency, and ultimately vaccine protection in humans.
引用
- Rudicell RS, Garinot M, Kanekiyo M, et al. Comparison of adjuvants to optimize influenza neutralizing antibody responses. Vaccine. 2019. PMID: 31493950. doi:10.1016/j.vaccine.2019.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。